A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-06-03
DOI
10.1111/bph.14383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- (2018) Michael J Curtis et al. BRITISH JOURNAL OF PHARMACOLOGY
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
- (2017) Simon D Harding et al. NUCLEIC ACIDS RESEARCH
- FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes
- (2017) Mark Z. Chen et al. Molecular Metabolism
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity
- (2016) Jun Yin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
- (2016) Ana L. Gomes et al. CANCER CELL
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Pathogenesis of nonalcoholic steatohepatitis
- (2016) Wensheng Liu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pathogenesis of Nonalcoholic Steatohepatitis
- (2016) Mariana Verdelho Machado et al. GASTROENTEROLOGY
- Extension of in vivo half-life of biologically active molecules by XTEN protein polymers
- (2016) Vladimir N. Podust et al. JOURNAL OF CONTROLLED RELEASE
- Fibroblast growth factor 21 night watch: advances and uncertainties in the field
- (2016) A. Kharitonenkov et al. JOURNAL OF INTERNAL MEDICINE
- Adiponectin Suppresses T Helper 17 Cell Differentiation and Limits Autoimmune CNS Inflammation via the SIRT1/PPARγ/RORγt Pathway
- (2016) Kai Zhang et al. MOLECULAR NEUROBIOLOGY
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
- (2016) Chi Ma et al. NATURE
- Nonalcoholic steatohepatitis (NASH) drugs market
- (2016) Sorcha Cassidy et al. NATURE REVIEWS DRUG DISCOVERY
- Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
- (2016) Giovanni Musso et al. NATURE REVIEWS DRUG DISCOVERY
- Immunology in the liver — from homeostasis to disease
- (2016) Felix Heymann et al. Nature Reviews Gastroenterology & Hepatology
- Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease
- (2016) Weilin Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
- (2016) Carla Melisa Chackelevicius et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Non-alcoholic fatty liver and the gut microbiota
- (2016) Stavros Bashiardes et al. Molecular Metabolism
- Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
- (2015) John C McGrath et al. BRITISH JOURNAL OF PHARMACOLOGY
- The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy
- (2015) Jia Liu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
- (2015) Alexei Kharitonenkov et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells
- (2015) Sayaka Shibata et al. Nature Communications
- Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD
- (2015) Takeshi Inagaki Frontiers in Endocrinology
- Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
- (2014) Monika Julia Wolf et al. CANCER CELL
- FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss
- (2014) Bryn M. Owen et al. Cell Metabolism
- The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target
- (2014) Wen-Yue Liu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- FGF21-based pharmacotherapy – potential utility for metabolic disorders
- (2014) Ruth E. Gimeno et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Inventing new medicines: The FGF21 story
- (2014) Alexei Kharitonenkov et al. Molecular Metabolism
- Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice
- (2013) Zhuofeng Lin et al. Cell Metabolism
- FGF21 Mimetic Shows Therapeutic Promise
- (2013) Marc L. Reitman Cell Metabolism
- An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
- (2013) William L. Holland et al. Cell Metabolism
- A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice
- (2013) Norihiro Kubota et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome
- (2013) Jun Zhang et al. DRUG DISCOVERY TODAY
- IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice
- (2013) Isaac T.W. Harley et al. HEPATOLOGY
- From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
- (2013) Alexander Wree et al. Nature Reviews Gastroenterology & Hepatology
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
- (2012) Y. Yilmaz ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones
- (2012) Paul A. Dutchak et al. CELL
- Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
- (2012) Naoki Tanaka et al. HEPATOLOGY
- Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2012) Yoshihisa Takahashi WORLD JOURNAL OF GASTROENTEROLOGY
- Acyl-coenzyme A synthetases in metabolic control
- (2010) Jessica M Ellis et al. CURRENT OPINION IN LIPIDOLOGY
- Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines
- (2010) Carol Kilkenny et al. JOURNAL OF GENE MEDICINE
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- Acyl-CoA synthesis, lipid metabolism and lipotoxicity
- (2009) Lei O. Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Induction and effector functions of TH17 cells
- (2008) Estelle Bettelli et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now